Prime Medicine, INC 8-K filings

Prime Medicine announced strong Q2 2026 results, highlighting regulatory advancements for PM577a and PM359, a favorable arbitration outcome for PM647, and a cash runway into 2027.

Prime Medicine announced a final arbitration award confirming its development candidate PM647 falls within its defined field, dismissing Beam Therapeutics' claims.

Prime Medicine, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of two Class I Directors and the ratification of its independent auditor.

Prime Medicine announced its first quarter 2026 financial results, highlighting progress in its gene editing therapies for Wilson Disease and AATD, with regulatory filings on track and initial clinical data expected in 2027.

Prime Medicine has appointed Svetlana Makhni as Chief Financial Officer, effective April 16, 2026, succeeding Dr. Allan Reine in the role.

Prime Medicine announced its full-year 2025 financial results and provided key business updates, including progress on its gene editing programs for Wilson Disease, AATD, and CGD.

Prime Medicine, Inc. announced an updated corporate presentation highlighting breakthrough clinical data for its Prime Editing platform and outlining key program advancements for Wilson Disease and AATD.

Prime Medicine announced its third quarter 2025 financial results and provided updates on its gene editing pipeline, including progress in Wilsons Disease and Alpha-1 Antitrypsin Deficiency programs.

Prime Medicine, Inc. has updated its corporate presentation, highlighting progress in its Prime Editing platform, positive clinical data for CGD, and pipeline advancements for Wilson's Disease and AATD.

Prime Medicine announced positive Phase 1/2 clinical data for its CGD program, providing clinical proof-of-concept for Prime Editing, alongside a strategic restructuring and successful capital raise.

Prime Medicine, Inc. stockholders approved a one-time repricing of certain outstanding stock options for employees and Board members to $4.04 per share.

Prime Medicine, Inc. has entered into an underwriting agreement for a public offering of 38 million common shares at $3.30 per share, aiming to raise approximately $120.2 million in net proceeds to fund key research and development initiatives.

Prime Medicine announced preliminary unaudited cash estimates of $101.8 million as of June 30, 2025, and terminated its at-the-market sales agreement prospectus while highlighting positive clinical data and pipeline progress.

Prime Medicine, Inc. announced that its Chief Scientific Officer, Dr. Jeremy Duffield, will step down from his role but will continue to provide consulting and advisory services through March 2026.

Prime Medicine, Inc. announced the successful re-election of Thomas Cahill, M.D., Ph.D. and Robert Nelsen as Class III Directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor at its 2025 annual meeting of stockholders.

Prime Medicine announces a strategic restructuring to focus on liver diseases and partnered programs, a CEO transition, and positive initial clinical data for its CGD program.

Prime Medicine announces first quarter 2025 financial results and provides a business update, highlighting advancements in its gene editing programs and anticipated clinical milestones.

Prime Medicine announces a preclinical program for AATD, demonstrating up to 72% precise gene correction in humanized mice and expecting to file an IND/CTA in mid-2026.

Prime Medicine is on track to report initial data from its Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 and expects to file an IND and/or CTA for PM577 for Wilson's Disease in the first half of 2026.

Prime Medicine is progressing its gene editing technology with multiple programs entering clinical stages and strategic collaborations to expand its reach and financial resources.

Prime Medicine reported its Q3 2024 financial results, highlighted by a strategic collaboration with Bristol Myers Squibb and advancements in its Wilsons Disease program.

Prime Medicine announced positive in vivo proof-of-concept data for its Wilson's Disease program, showcasing the potential of its universal liver-targeted LNP platform at the ESGCT 31st Annual Congress.

Prime Medicine has entered a strategic research collaboration and license agreement with Bristol Myers Squibb, receiving $110 million upfront and potentially over $3.5 billion in milestones, while also focusing its pipeline on high-value programs.

Prime Medicine reports its second quarter 2024 financial results, highlighted by FDA clearance to advance PM359 into clinical trials and the promotion of Dr. Mohammed Asmal to Chief Medical Officer.

Prime Medicine's stockholders approved an amendment to the company's charter to limit officer liability and elected four Class II directors at their annual meeting on June 12, 2024.

Prime Medicine's Board of Directors has adopted amended bylaws to update procedures for stockholder proposals, director nominations, and meeting protocols.

Prime Medicine reported its first quarter 2024 financial results, highlighted by FDA clearance for its first Prime Editing product, PM359, and provided updates on its broader pipeline and platform.

Prime Medicine announced its full year 2023 financial results and provided a business update, highlighting its progress towards becoming a clinical-stage company with its Prime Editing technology.

Prime Medicine, Inc. has entered into an underwriting agreement for a public offering expected to generate approximately $150.9 million in net proceeds to fund research and development.

Prime Medicine reports preliminary unaudited cash, cash equivalents, and short-term investments of approximately $135.2 million as of December 31, 2023.